Literature DB >> 22831178

The utilization of solid organs for transplantation in the setting of infection with multidrug-resistant organisms: an expert opinion.

Jihad Bishara1, Elad Goldberg, Shaul Lev, Pierre Singer, Tamar Ashkenazi, Jonathan Cohen.   

Abstract

Organ transplantation remains the optimal treatment for many patients suffering from end-stage organ disease. Increasing numbers of patients admitted to intensive care units, among them potential heart-beating, brain-dead organ donors, are exposed to infections with multidrug-resistant organisms, in particular carbapenem-resistant Klebsiella pneumoniae (CR-KP). An extensive literature search failed to reveal any information regarding the eligibility for transplantation of organs from such donors. For this reason, in 2009, the Israel Transplant Center, together with the Israeli Society for Infectious Diseases, established a working group with the intention of developing a national-specific approach to the use of these organs. In this viewpoint article, we present an algorithm based on expert opinion and our clinical experience with a donor who was found to be an asymptomatic carrier of CR-KP.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2012        PMID: 22831178     DOI: 10.1111/j.1399-0012.2012.01693.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  9 in total

1.  Multidrug-resistant bacteria in organ transplantation: an emerging threat with limited therapeutic options.

Authors:  Gopi Patel; Meenakshi M Rana; Shirish Huprikar
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

Review 2.  Multidrug-resistant Gram-negative bacteria in solid organ transplant recipients with bacteremias.

Authors:  Q Q Wan; Q F Ye; H Yuan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-11-12       Impact factor: 3.267

3.  Transmission of methicillin-resistant Staphylococcus aureus infection through solid organ transplantation: confirmation via whole genome sequencing.

Authors:  J M Wendt; D Kaul; B M Limbago; M Ramesh; S Cohle; A M Denison; E M Driebe; J K Rasheed; S R Zaki; D M Blau; C D Paddock; L K McDougal; D M Engelthaler; P S Keim; C C Roe; H Akselrod; M J Kuehnert; S V Basavaraju
Journal:  Am J Transplant       Date:  2014-09-22       Impact factor: 8.086

Review 4.  Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies.

Authors:  Stephanie M Pouch; Michael J Satlin
Journal:  Virulence       Date:  2016-07-28       Impact factor: 5.882

Review 5.  Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplantation: Management Principles.

Authors:  Olivia Smibert; Michael J Satlin; Anoma Nellore; Anton Y Peleg
Journal:  Curr Infect Dis Rep       Date:  2019-06-10       Impact factor: 3.725

Review 6.  Multidrug-resistant bacterial infections after liver transplantation: an ever-growing challenge.

Authors:  Guilherme Santoro-Lopes; Erika Ferraz de Gouvêa
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 7.  Antibiotic prophylaxis for surgical site infection in people undergoing liver transplantation.

Authors:  Ricardo A M B Almeida; Claudia N Hasimoto; Anna Kim; Erica N Hasimoto; Regina El Dib
Journal:  Cochrane Database Syst Rev       Date:  2015-12-05

8.  Fatal Donor-Derived Carbapenem-Resistant Klebsiella pneumoniae Infection in a Combined Kidney-Pancreas Transplantation.

Authors:  Giovanni Varotti; Ferdinando Dodi; Anna Marchese; Alessia Terulla; Massimo Bertocchi; Iris Fontana
Journal:  Case Rep Transplant       Date:  2016-10-16

9.  Fatal case of donor-derived colistin-resistant carbapenemase-producing Klebsiella pneumoniae transmission in cardiac transplantation.

Authors:  Lisia Miglioli Galvão; Anna Paula Romero de Oliveira; Aline Santos Ibanês; Jussimara Monteiro; Fernanda Inoue; Daniel Chagas Dantas; Flavio Sanchez; Daniel Wagner Santos; Cely Saad Abboud
Journal:  Braz J Infect Dis       Date:  2018-05-26       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.